ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced the co...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated wi...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10%...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced it will regain development and commercialization rights to giroctocog...
Novartis announced positive topline results from the Phase III STEER study. This pivotal study assessed the efficacy and safety of investigational intrathe...
The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal...
Janssen-Cilag International NV, a Johnson & Johnson company, announced the European Commission (EC) approval of RYBREVANT®▼ (amivan...
-Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig™&nbs...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, an...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...
Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Appl...
the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like pep...
Keymed Biosciences Inc. (HKEX: 02162) announced the National Medical Products Administration (the "NMPA") of China has recently approved the supp...
Bristol Myers Squibb (NYSE: BMY) announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evalua...
© 2025 Biopharma Boardroom. All Rights Reserved.
